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Background: Traditional Chinese medicine (TCM) has been used to treat chronic obstructive pulmonary disease
(COPD) for many years. This study aimed to evaluate the efficacy and safety of the comprehensive therapy based
on the three common TCM patterns in stable COPD patients.
Methods: A four-center, open-label randomized controlled method was conducted. A total of 352 patients were
divided into the trial group (n = 176, treated with conventional Western medicine and Bu-Fei Jian-Pi granules,
Bu-Fei Yi-Shen granules, and Yi-Qi Zi-Shen granules based on the TCM patterns respectively) and the control group
(n = 176, treated with conventional Western medicine). The frequency and duration of acute exacerbation, lung
function, clinical symptoms, 6-minute walking distance (6MWD), dyspnea scale and quality of life were observed
during a 6-month treatment period and at a further 12-month follow-up.
Results: A total of 306 patients completed the study fully. The full analysis set (FAS) population was 350 and the
per-protocol analysis set (PPS) population was 306. After the 6-month treatment and 12-month follow-up, there
were significant differences between the trial and control group in the following: frequency of acute exacerbation
(FAS: P = 0.000; PPS: P = 0.000); duration of acute exacerbation (FAS: P = 0.000; PPS: P = 0.001); FEV1 (FAS: P = 0.007;
PPS: P = 0.008); symptoms (FAS: P = 0.001; PPS: P = 0.001); 6MWD (FAS: P = 0.045; PPS: P = 0.042); dyspnea scale
(FAS: P = 0.002; PPS: P = 0.004); and physical domain (FAS: P = 0.000; PPS: P = 0.000), psychological domain (FAS:
P = 0.008; PPS: P = 0.011), social domain (FAS: P = 0.001; PPS: P = 0.000) and environment domain (FAS: P = 0.015;
PPS: P = 0.009) of the WHOQOL-BREF questionnaire. There were no differences between the trial and control group
in FVC, FEV1% and adverse events.
Conclusions: Based on the TCM patterns, Bu-Fei Jian-Pi granules, Bu-Fei Yi-Shen granules and Yi-Qi Zi-Shen
granules have beneficial effects on measured outcomes in stable COPD patients over the 6-month treatment and
12-month follow-up, with no relevant between-group differences in adverse events.
Trial Registration: This trial was registered at Chinese Clinical Trial Register Center, ChiCTR-TRC-11001406.
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Chronic obstructive pulmonary disease (COPD) is a major
public health problem throughout the world. The high
prevalence, morbidity, mortality and economic burdens of
COPD are increasing steadily. The projection for 2020
indicates that COPD will become the third leading cause
of death worldwide [1]. Because of tobacco smoking,
solid-fuel use, and other reasons, an estimated 65 million
people will die of COPD between 2003 and 2033 in China
[2]. Therefore, designing strategies and treatments for
COPD is important. In light of evidence-based medicine,
short-acting bronchodilators, long-acting bronchodilators,
inhaled glucocorticosteroids, and low-dose, slow-release
theophylline are the established interventions for treating
COPD patients [3]. However, it is difficult to improve peo-
ple’s symptoms without suffering too many side effects or
adverse events [4].
The remarkable longevity and current popularity of
traditional Chinese medicine (TCM) for COPD implies
its potential advantages in ameliorating symptoms, redu-
cing the frequency of acute exacerbation, and improving
quality of life on the basis of different patterns and
stages [5,6]. There is limited evidence for randomized
controlled trials on comprehensive TCM interventions,
especially based on the TCM patterns. Therefore it is
difficult to fully reflect the efficacy, characteristics and
advantages of TCM [7]. The TCM pattern is a specific
stratification of a disease according to a group of symp-
toms, which can be regarded as a summary of the body’s
condition at a certain stage in a disease process [8]. A
potential way of studying COPD is by adopting the
method of TCM patterns in clinical practice. According
to our previous study, there are three common TCM
patterns of stable COPD, and there is one specific herbal
intervention responding to each pattern, which reflects
the concepts of individualized therapy of TCM [9]. There-
fore, we performed a multi-center randomized controlled
study that had been carried out to evaluate the efficacy
and safety of comprehensive interventions based on the
three TCM patterns in patients with stable COPD.Methods
Participants
Diagnostic criteria
COPD was diagnosed by the Global Strategy for the
Diagnosis, Management, and Prevention of COPD, and
the Chinese Treatment Guidelines of COPD [10,11].Traditional Chinese medicine pattern criteria
The TCM pattern criteria of stable COPD were estab-
lished by literature analysis, clinical investigation, expert
counseling, scientific assessment and clinical application
[9,12]. There are three common patterns as follows.Pattern of lung-spleen qi deficiency: Symptoms of lung-
spleen qi deficiency included the following: (1) coughing
and shortness of breath which are worse when active;
(2) lassitude and spontaneous sweating, which are worse
when active; (3) being prone to catching a cold; (4) poor
appetite or eating less; (5) bloating in the gastric cavity, ab-
dominal distension or loose stools; and (6) an enlarged
tongue with a white or greasy fur and deep thready pulse,
deep slow pulse or thready weak pulse. As long as the
patients showed any two of symptoms (1), (2), or (3),
along with any two of symptoms (4), (5), or (6), the pat-
tern of lung-spleen qi deficiency was diagnosed.
Pattern of lung-kidney qi deficiency: Symptoms of lung-
kidney qi deficiency included the following: (1) panting,
shortness of breath, which are worse when active; (2) lassi-
tude and spontaneous sweating, which are worse when
active; (3) being prone to catching a cold; (4) weakness in
the lower back and knees; (5) tinnitus, vertigo, or asthenia
facial edema; (6) profuse urine, frequent urination at night,
or urine released with coughing; and (7) a pale tongue
with white fur, deep thready pulse or thready weak pulse.
As long as the patients showed any two of symptoms (1),
(2), or (3), along with any two of symptoms (4), (5), (6),
or (7), the pattern of lung-kidney qi deficiency was
diagnosed.
Pattern of lung-kidney qi and yin deficiency: Symp-
toms of lung-kidney qi and yin deficiency included the
following: (1) panting and shortness of breath, which are
worse when active; (2) lassitude, which is worse when
active; (3) being prone to catching a cold; (4) weakness
in the lower back and knees; (5) tinnitus and dizziness;
(6) a dry cough or scanty sputum and difficult in spit-
ting; (7)spontaneous sweating or night sweating; (8) fe-
verishness in the palms and soles; and (9) a pale or red
tongue with thin and little fur, and a thready pulse,
thready weak pulse or thready rapid pulse. As long as
the patients showed any two of symptoms (1), (2), or (3),
along with any one of symptoms (4), or (5), and any two
of the symptoms (6), (7), (8), or (9), the pattern of lung-
kidney qi and yin deficiency was diagnosed.Inclusion criteria
Patients were included in the study according to the fol-
lowing: (1) patients met the diagnostic criteria; (2) patients
met the TCM pattern criteria of stable COPD (TCM diag-
nosis); (3) patients were stable and met the diagnosis of
mild to severe COPD (Global Initiative for Chronic
Obstructive Lung Disease, GOLD 1,2,3); (4) patients were
aged between 40 to 80 years; (5) patients underwent a two-
week wash-out period prior to randomization; (6) patients
had no experience in other interventional trials in the pre-
vious 1 month; and (7) patients should receive the treat-
ment voluntarily and sign informed consent.
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Patients were excluded from the study for the following
reasons: (1) acute exacerbation of COPD or very severe
COPD (GOLD 4); (2) female patients were in pregnant
or breast-feeding; (3) confusion, dementia or any type of
mental illness that rendered patients unable to under-
stand the nature, scope and possible consequences of
the study; (4) patients were complicated by severe heart
failure (Grade II or IV New York Heart Association
[NYHA] Functional Classification); (5) patients were
complicated with bronchial asthma, bronchiectasis, ac-
tive tuberculosis, pulmonary embolism or diffuse pan-
bronchiolitis; (6) patients were complicated with a
neuromuscular disorder, which affected the respiration;
(7) patients with serious hepatic and renal diseases, such
as liver cirrhosis, portal hypertension, bleeding of vari-
cose veins, dialysis, or renal transplantation; (8) congeni-
tal or acquired immune deficiency; (9) participation in
other clinical intervention research; and (10) allergies to
treatment drugs.
Ethics and trial registration
The study was approved by the Ethical Research Commit-
tees of The First Affiliated Hospital of Henan University
of Traditional Chinese Medicine (batch number:
YFYKTLL2007-1). The study was registered at the
Chinese Clinical Trial Register Center (ChiCTR-TRC-
11001406).
Entry procedure
Patients with stable COPD were enrolled from either the
out-patient department or open recruitment and were
observed in four centers, including the First Affiliated
Hospital of Henan University of Traditional Chinese
Medicine, Jiangsu Provincial Hospital of Traditional
Chinese Medicine, Henan Provincial People’s Hospital
and the Affiliated Hospital of Shandong University of
Traditional Chinese Medicine. All patients signed the
informed consent before inclusion.
Study design
Sample Size
A total of 352 cases were divided into the trial group
(n=176) and the control group (n=176). The frequency
of acute exacerbation was considered as the primary out-
come. From a previous study, the number of the exacer-
bation frequency decreased by 0.44 times every half year
by the TCM comprehensive interventions compared
with the Western medicine treatment [13]. We assumed
that when the number of exacerbation frequency was
decreased at least by 1 times between the two groups
and the standard deviation was 1.5 times/year, the efficacy




based on a comparison between the equal numbers of a
two sample mean. The two-sided alpha level was 0.05, and
the beta level was 0.10. The δ value was 1, the σ value was
1.5, the μα value was 1.96, the μβ value was 1.28. Using the
calculation, N=2*(1.96+ 1.28) 2*1.52/1.02, the sample size
in each group was approximately 48. If the severity of
airflow limitation in COPD (GOLD 1, 2, 3) was considered
as the stratification factor, and the stratification factor was
3, then 144 (48*3) patients were required in each group,
and the sample size in the two groups would be 288
(144*2). Allowing for a 15% dropout rate over the course
of the study, the sample size would be approximately 332
(288+288*0.15). The sample size was inflated to allow for
the balance of the research centers, with two patients were
added to each group, and therefore the sample size was
336 (332+2*2). To avoid the negative effect of accidents in
clinical implementation, four patients were also added
in each research center. The number of research cen-
ters was four, and therefore, the final sample size was
352 (336+4*4), with 176 patients in each group.
Randomization
A stratified and block randomization design was
adopted. The number of the groups was 2 and the distri-
bution ratio was 1-to-1. Considering the long time for
treatment observation, the process was divided into
more than one block, and the length of the block was
four. The number of center hierarchical levels was four.
A random number from 001 to 352 was generated by
SAS 9.2 and saved in a sealed envelope by an independ-
ent clinical statistician. Treatment allocation occurred
when the participant met the inclusion criteria and
signed the informed consent form. In the event of a clin-
ical emergency, the individual’s randomization code and
group allocation could be identified by the emergency
envelope as soon as possible. The randomization design
was provided by the DME department of Guangzhou
University of Traditional Chinese Medicine.
The study was an open-label trial, however, some mea-
sures were taken to strengthen quality control. An inves-
tigator separate from all of the clinical researchers was
assigned in each research center as the contact person
who preserved and recorded the randomization informa-
tion. Therefore, the clinical researchers did not have any
effect on enrollment or randomization. Meanwhile out-
come assessments were made by an independent clinical
statistician blinded to group allocation and uninvolved
in providing intervention or management.
Interventions
Patients in the control group were given conventional
Western medicine treatment based on the classes of
Table 2 Main components of traditional Chinese
medicine treatment
Chinese name Latin name Amount (g)
Bu-Fei Jian-Pi granules
Huang Qi Astragalus propinquus 15
Dang Shen Codonopsis pilosula 15
Bai Zhu Atractylodes macrocephala 12
Fu Ling Wolfiporia extensa 12
Chuan Bei Mu Fritillaria cirrhosa 9
Bu-Fei Yi-Shen granules
Ren Shen Radix Ginseng 9
Huang Qi Astragalus propinquus 15
Gou Qi Zi Lycium barbarum 12
Shan Zhu Yu Cornus officinalis 12
Yin Yang Huo Epimedium brevicornu 9
Yi-Qi Zi-Shen granules
Ren Shen Radix Ginseng 9
Huang Jing Polygonatum sibiricum 15
Shu Di Huang Rehmannia glutinosa 15
Mai Dong Ophiopogon japonicus 15
Wu Wei Zi Schisandra chinensis 9
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Chronic Obstructive Lung Disease (GOLD) and Chinese
Treatment Guidelines of COPD [10,11]. The specific
therapies were shown in Table 1. For the trial group,
which was given conventional Western medicine treat-
ment, patients were additionally given Bu-Fei Jian-Pi
granules for lung-spleen qi deficiency, Bu-Fei Yi-Shen
granules for lung-kidney qi deficiency, and Yi-Qi Zi-
Shen granule for lung-kidney qi and yin deficiency.
The TCM granules were compound preparations of
TCM and its components are shown in Table 2. These
components were produced and packed by Jiang Yin
Tian Jiang Pharmaceutical Co. Ltd. with the authentica-
tion quality of Goods Manufacturing Practice (Approval
Number: SU J0677), Jiangsu, PR China. The test results
of drug quality were consistent with the required quality
standards.
Bu-Fei Jian-Pi granules (batch number: 080103), came
in packs of six bags, and each bag contained 3.83 g. Bu-
Fei Yi-Shen granules (batch number: 080102), came in
packs of six bags, and each bag contained 4.25 g. Yi-Qi
Zi-Shen granules (batch number: 080104), came in packs
of six bags, and each bag contained 5.16 g. Each type of
granule was given orally, three bags each time, twice a
day for 6 months.Outcomes
Frequency and duration of acute exacerbation of COPD
Acute exacerbation of COPD (AECOPD) refers to the
patients' acute exacerbation of their original conditions
of dyspnea, cough, and (or) expectoration in the devel-
opment of the disease, which exceeds the daily routine
variation, and requires a change in treatment. During
the course of AECOPD, patients with aggravation of
shortness of breath are often accompanied by dyspnea,
chest tightness, a worse cough, increased sputum vol-
ume, changes in color, and (or) viscosity of sputum and
fever [14].
The frequency and duration of AECOPD each time
during treatment were recorded for 6 months and at a
follow-up survey for 12 months. If the interval betweenTable 1 Therapy at each stage of stable COPD
Classification Lung function
I: Mild FEV1/FVC<0.70, FEV1≥80%
predicted
Active reduction of risk fact
(inhalation aerosol, Ventolin
Dosing: 1–2 inhalations of 1
II: Moderate FEV1/FVC<0.70,
50%≤FEV1<80% predicted
Based on therapy of GOLD 1
fumarate dehydrate (Inhalati
Dosing: one inhalation of 4
III:Severe FEV1/FVC<0.70,
30%≤FEV1<50% predicted
Based on therapy of GOLD 2
fluticasone propionate ([dry
Dosing: one inhalation of 2two onsets of acute exacerbation was within 1week, it
was counted as one time of acute exacerbation.
Lung function
The indicators of forced vital capacity (FVC), forced ex-
piratory volume in one second (FEV1) and FEV1 per-
centage of the predicted value (FEV1%) were tested.
Symptoms
Symptoms included coughing, sputum, shortness of
breath, dyspnea, gasping, and cyanosis. Based on the
typical format of a Likert response scale [15], each symp-
tom had a score from 0 to 3 according to the severity of
the symptom. The lower the score, the better the clinical
symptom of the patients. Total scores were got by add-
ing up each symptom score.Therapy
ors; add short-acting bronchodilator (when needed), i.e. albuterol sulfate
, GlaxoSmithKline), 100μg/dose, 200 inhalations.
00 μg each time, and the maximum dose is 8–12 inhalations a day.
; add regular treatment with one long-acting bronchodilators,i.e.formoterol
on powder, Oxis Turbuhaler, AstraZeneca), 4.5μg/dose, 60 inhalations.
.5μg each time, twice daily
; add inhaled glucocorticosteroids if repeated exacerbations,i.e. salmeterol/
powder inhaler], Seretide, GlaxoSmithKline), 50/250 μg/dose, 60 inhalations .
50/50 μg each time, twice daily
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The 6MWD [16] was measured by the 6-minute walking
test (6MWT) which evaluated the distance a person can
walk on a flat surface in six minutes.
Dyspnea scale questionnaire
The Dyspnea Scale Questionnaire was firstly developed
by the British Medical Research Council [17] (MRC) and
later modified by the American Thoracic Society [18],
and it contains 5 grades, ranging from 0 to 4.
Quality of life
The World Health Organization of Life-BREF (WHO-
QOL-BREF) instrument [19] was adopted, which con-
taines 26 questions in 4 domains, including physical,
psychological, society, and environment domains. In
each domain, the higher the score of the questionnaire,
the better the quality of life of the patients.
Safety
Routine blood, urine, and stool tests, liver and kidney
function tests, and an electrocardiogram were per-
formed. Adverse events were recorded at any time dur-
ing the treatment period and follow-up period.
We recorded the dates when lung function, symptoms,
6MWD, the Dyspnea Scale Questionnaire, and quality of
life were observed before treatment (month 0), in the
3rd month (month 3) and 6th month (month 6) during
the treatment period, and at the 12th month (month 18)
during the follow-up period. The date of AECOPD was
observed and calculated at month 0, month 6, and




A full analysis set (FAS) was used to analyze the baseline
data and clinical evaluation data of the cases who went
through randomization and received treatments, and
were observed at least one related record on time point.
Partially missing data of the clinical evaluation were car-
ried forward with the principle of the last visit carried
forward (LOCF). A per-protocol analysis set (PPS) was
used to analyze the clinical evaluation data of the cases
who fully completed the trial with better compliance. A
safety set (SS) was used to analyze the safety data of the
cases who took the trial medicine at least once.
Data processing and statistical analysis methods
All P values were two-tailed and the α level of signifi-
cance was set at 0.05. Measurement data were described
by mean and standard deviation x SDð Þ or median.
Independent-samples t-tests or Mann–Whitney U-tests
were used based on data distribution to comparedifferences between the two groups. The paired samples
t-tests or signed rank sum test was used based on data
distribution to compare differences between pre-
treatment and post-treatment within one group.
Repeated measures were used to compare differences of
time continuous observations. Numercial data are
described by constituent ratio. The chi-square test was
used to compare differences in safety between the trial
group and control group. All statistical analyses were
undertaken using SAS9.2 (KEY: FQ37-WSB8-7G5C).
Results
Study population
A total of 637 COPD patients were enrolled and
assessed for eligibility, through the 2-week washout
period, and 352 patients underwent randomization
(Figure 1). Based on the withdrawal and rejection cri-
teria, two patients who violated the protocol were
excluded. Forty-four patients who did not fully complete
the study were withdrawn because of poor compliance,
being lost to follow up, or dropped out of the study
without explanation. A total of 306 patients fully com-
pleted the study, with 155 in the trial group and 151 in
the control group. Therefore, the PPS population was
306. The clinical evaluation data of the 44 patients who
did not fully complete the study, but received treatment
and also completed observation at least one related rec-
ord on time point were analyzed. These data were evalu-
ated by intent-to-treat analysis according to the principle
of the last visit carried forward (LOCF). Therefore, the
FAS population was 350, with 175 in the trial group and
175 in the control group.
Demographic and baseline characteristics of the patients
are shown in Table 3. There was no significant difference
in gender, age, the course of disease, body mass index
(BMI), exacerbations, lung function, and GOLD classifica-
tion of lung function between the two groups.
Comparison of the frequency and duration of acute
exacerbation
Before treatment, there was no significant difference in
the frequency of acute exacerbation between the two
groups (FAS: P = 0.169; PPS: P = 0.129). For the time
point of month 6 and month 18, there was a significant
difference in the frequency of acute exacerbation between
the trial and control groups (FAS: P = 0.001, P = 0.000;
PPS: P = 0.004, P = 0.000). The average frequency of acute
exacerbation and the constituent ratio of frequency were
significantly different between the trial and control groups
(FAS: P = 0.000, P = 0.000; PPS: P = 0.000, P = 0.000). At
6 and 18 months, the average duration of acute exacerba-
tion was significantly different between the trial and the
control groups (FAS: P = 0.000; PPS: P = 0.001). The
results were shown in Table 4.
Figure 1 Enrollment of the patients and completion of the study.
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FEV1 was significantly higher over time in the trial group,
compared with that in the control group (FAS: P = 0.007;
PPS: P = 0.008). At 3, 6, and 18 months, FEV1 was signifi-
cantly higher in the trial group compared with that in the
control group (FAS: P = 0.032, P = 0.047, P = 0.001; PPS:
P = 0.015, P = 0.021, P = 0.001). There were no significant
difference in FVC, FEV1% between the two groups (FAS:
P = 0.147, P = 0.204; PPS: P = 0.112, P = 0.126)
(Figure 2A,B,C).
Comparison of symptoms and the dyspnea scale
There was no significant difference in total scores of symp-
toms and the dyspnea scale between the two groups before
treatment (symptoms, FAS: P = 0.859; PPS: P = 0.745; dys-
pnea scale, FAS: P = 0.322; PPS: P = 0.503). The total
scores of symptoms and the dyspnea scale of trial group
was significantly lower over time compared with those of
the control group (FAS: P = 0.001, PPS: P = 0.001; FAS:
P = 0.002; PPS: P = 0.004). At 3, 6 and 18 months, there
was significant difference in total scores of symptoms and
the dyspnea scale in the trial group compared with those
in the control group (symptoms, FAS: P = 0.000, P = 0.000,
P = 0.000; PPS: P = 0.000, P = 0.000, P = 0.001; dyspneascale, FAS: P = 0.008, P = 0.000, P = 0.000; PPS: P = 0.014,
P = 0.001, P = 0.000) (Figure 2D, F).
Comparison of 6MWD
There was no significant difference in the mean value of
6MWD between two groups before treatment and month
3 (FAS: P = 0.986, P = 0.05; PPS: P = 0.781, P = 0.064).
The mean value of 6MWD in the trial group was signifi-
cantly higher over time than that of the control group
(FAS: P = 0.045; PPS: P = 0.042). At 6 and 18 months, the
mean value of 6MWD were significantly higher in trial
group compared with the control group (FAS: P = 0.004,
P = 0.009; PPS: P = 0.003, P = 0.009) (Figure 2E).
Comparison of quality of life
Before treatment, there was no significant difference in the
quality of life scores in each domain between the groups
(physical domain, FAS: P = 0.885; PPS: P = 0.943; psycho-
logical domain, FAS: P = 0.884; PPS: P = 0.723; social do-
main, P = 0.979; PPS: P = 0.884; environment domain, FAS:
P = 0.763, PPS: P = 0.107). Quality of life scores of the trial
group continued to increase over time, and the mean scores
of the trial group were significantly higher than those of the
control group (physical domain, FAS: P = 0.000, PPS:
Table 3 Baseline characteristics of the patients
Characteristics Full analysis set Per-protocol analysis set
Trial n=175 Control n=175 t/χ2/Z P Trial n=155 Control n=151 t/χ2/Z P
Age (years) 66.33 ± 9.63 64.28 ± 9.42 −0.935 0.351 62.74 ± 9.87 64.66 ± 8.92 −1.778 0.076
Course of disease△ 169.56 ± 290.63 161.07 ± 128.45 0.353 0.725 166.86 ± 305.92 163.18 ± 131.84 0.136 0.892
BMI▲ 24.26 ± 11.79 23.75 ± 3.10 0.543 0.587 24.41 ± 12.54 23.74 ± 3.09 0.643 0.521
Exacerbation□
Frequency (times) 3.26 ± 2.27 2.94 ± 2.05 1.378 0.169 3.32 ± 2.31 2.95 ± 1.91 1.523 0.129
Duration (days) 2.78 ± 2.00 2.73 ± 1.97 0.228 0.820 2.82 ± 2.08 2.75 ± 1.81 0.319 0.750
Lung function■
FVC (liters) 2.91 ± 0.95 2.81 ± 0.89 0.953 0.341 2.95 ± 0.97 2.81 ± 0.92 1.239 0.216
FEV1(liters) 1.46 ± 0.57 1.35 ± 0.46 1.465 0.144 1.46 ± 0.57 1.35 ± 0.46 1.747 0.082
FEV1% 49.89 ± 10.84 49.58 ± 12.07 0.244 0.807 49.94 ± 10.95 49.58 ± 12.36 0.266 0.790
Gender
Male 122 131 1.556 0.212 106 116 2.732 0.098
Female 54 43 49 35
Smoking status
Currently smoking 103 114 1.817 0.178 89 102 3.346 0.067
None-smoking 73 60 66 49
Smoking pack-years 380.91 ± 158.26 366.47 ± 150.32 0.686 0.493 377.08 ± 164.08 372.47 ± 154.47 0.199 0.843
GOLD classification
GOLD 1 14 6 −0.093 0.926 13 6 −0.369 0.712
GOLD 2 68 80 61 66
GOLD 3 94 88 81 79
△The course of disease was calculated in months.
▲The body-mass index (BMI)is the weight in kilograms divided by the square of the height in meters.
□Exacerbations during the 12 months before screening were self-reported.
■Clinical data are from visit 1 (the screening visit). FEV1 denotes forced expiratory volume in 1 second, and FVC is forced vital capacity.
Li et al. BMC Complementary and Alternative Medicine 2012, 12:197 Page 7 of 11
http://www.biomedcentral.com/1472-6882/12/197P = 0.000; psychological domain, FAS: P = 0.000, PPS:
P = 0.000; social domain, FAS: P = 0.000, PPS: P = 0.000;
environment domain, FAS: P = 0.000, PPS: P = 0.000). At 3,
6, 18 months, the trial group had higher quality of life
scores compared with those of the control group (physical
domain, FAS: P = 0.022, P = 0.000, P = 0.001; PPS: P =Table 4 Comparison of the frequency and duration of acute e
Variable Full analysis set
Trial n=175 Control n=175 t/Z
Frequency (times)
Month 0 3.26 ± 2.27 2.94 ± 2.05 1.378
Month 6 1.02 ± 1.51 1.71 ± 2.14 −3.484
Month 18 0.49 ± 0.77 1.09 ± 1.15 −5.689
Average frequency 1.01 ± 1.26 1.95 ± 1.88 −5.509
Frequency (constituent ratio)
Have exacerbation 101 136 18.5857
None exacerbation 76 37
Duration(days)
Average duration 4.20 ± 5.20 6.22 ± 5.15 −3.6530.018, P = 0.000, P = 0.001; psychological domain, FAS: P =
0.049, P = 0.001, P = 0.003; PPS: P = 0.045, P = 0.001, P =
0.003; social domain, FAS: P = 0.016, P = 0.000, P = 0.000;
PPS: P = 0.006, P = 0.000, P = 0.000; environment domain,
FAS: P = 0.044, P = 0.001, P = 0.006; PPS: P = 0.045, P =
0.001, P = 0.006) (Figure 3A, B, C, D).xacerbation
Per-protocol analysis set
P Trial n=155 Control n=151 t/Z P
0.169 3.32 ± 2.31 2.95 ± 1.91 1.523 0.129
0.001 0.97 ± 1.26 1.48 ± 1.81 −2.888 0.004
0.000 0.54 ± 0.75 1.01 ± 0.98 −4.798 0.000
0.000 1.02 ± 1.08 1.76 ± 1.47 −4.963 0.000
0.000 92 121 15.6084 0.000
63 30
0.000 4.39 ± 5.24 6.37 ± 5.19 −3.323 0.001
Figure 2 Comparison of the results of FVC, FEV1, FEV1%, Total Scores of symptoms, 6MWD and Dyspnea Scale.
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There were no significant differences in routine blood,
urine and stool tests, liver and kidney function tests, and
electrocardiogram in each group before and after treat-
ment. There were no serious adverse events during the
treatment and follow-up period of the trial. However, ad-
verse events were recorded during treatment and follow-
up, but there was no significant difference in adverse
events between the two groups (P > 0.05). In the trial
group, five cases had adverse events that may have been
caused by drug-related effects of TCM treatment com-
bined with conventional Western medicine. Among
these five cases, one case had abdominal distension, one
case had palpitation, one case had constipation, one case
had thirst, and one case had insomnia. In the control
group, eight cases had adverse events that may have
been caused by drug-related effects of conventional
Western medicine. Among these eight cases, one case
had abdominal distension, one case had palpitation, one
cases had constipation, one case had thirst, one case had
insomnia, and one cases had stomach discomfort, one
cases had dry throat.
Discussions
COPD is a common and deadly disease that is character-
ized by persistent and progressive airflow limitation.
Therefore, exacerbations and comorbidities contribute
to overall severity in individual patients. Presently, the
classes of medications recommended by GOLD arecommonly used in treating COPD. Although more alter-
native approaches are used in COPD patients, definite
effect evidence for TCM treatment is still limited.
Hence, based on conventional Western medicine that re-
ferred to the GOLD classes of medications, we con-
ducted our study to evaluate the efficacy and safety of
TCM treatment by measuring such outcomes, scuh as
exacerbations, lung function, symptoms, exercise toler-
ance and quality of life.
The TCM treatment in this study included Bu-Fei
Jian-Pi granules, Bu-Fei Yi-Shen granules and Yi-Qi Zi-
Shen granules. These granules are made from highly
concentrated, selected Chinese herbs, and are produced
in accordance with a traditional Chinese formula. The
choice within each granule depends on the patient-
specific pattern on which based the TCM theory of lung,
spleen and kidney and Chinese medicine pattern theory.
Over the 6-month treatment and 12-month follow-up,
the TCM granules had beneficial effects on the mea-
sured outcomes, with no relevant between-group differ-
ences in adverse events.
AECOPD and lung function were the primary out-
comes in this study. AECOPD can affect a decrease in
lung function and impair the health-related quality of
life [20]. It has been reported that the in patients admit-
ted to intensive care units for AECOPD, their mortality
rate was about 11–24% [21,22]. Therefore, the reduc-
tions in the frequency and duration of exacerbations are
a major goal of COPD management and an important
Figure 3 Comparison of the results of WHOQOL-BREF physical field, psychological field, social field, and environment field.
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ated decline in lung function is the main hallmark of
COPD. A previous study showed that the rate of decline
in FVE1 in COPD patients decreased from 47 ml to
69 ml per year [24]. According to the results from the
well-known UPLIFT Trial and TORCH Trial, the rate of
decline in FVE1 in the salmeterol/fluticasone group was
39 ml/yr and the rate of decline in the tiotropium group
was 41 ml/yr [4,25]. Our results showed that the fre-
quency and the duration of AECOPD in the trial group
was 1.02 times and 4.39 days, respectively; however,
those in the control group were 1.76 times and 6.37 days
respectively. The rate of decline in FVE1 in patients in
the trial group increased by approximately 4.16 ml per
year, and it decreased approximately 52.54 ml/yr in the
control group. The rate of decline in FVE1 in patients
in the control group was consistent with that of previ-
ous large trials. TCM granules can reduce the frequency
and duration of acute exacerbation, and maintain the
rate of decline in FEV1. This may be due to the com-
bined effect of conventional Western medicine and
Chinese medicines.
Symptoms, exercise tolerance and health status out-
comes were also observed in the current study. The
characteristic symptoms of COPD are chronic and pro-
gressive dyspnea, cough, and sputum production.Although COPD is defined on the basis of airflow limita-
tion, in practice the decision to seek medical help is usu-
ally determined by the effect of a symptom on a patient’s
daily life. However, in an early or stable state, dyspnea is
not obvious and often overlooked by patients and physi-
cians [26]. Evaluation of the degree in breathing diffi-
culty is important to understand the severity of COPD,
the health status of patients and to evaluate clinical
intervention effects. Therefore, observations of symp-
toms and the Dyspnea Scale questionnaire were used in
the current study [27]. The 6MWD is widely used in re-
spiratory disease as a comprehensive evaluation of func-
tional status of the body with moderate or severe disease
[28]. The main objective of the 6MWD is to determine
exercise tolerance and oxygen saturation during sub-
maximal exercise. The 6MWD is also considered useful
in the determination of the point at which patients
should be listed for rehabilitation programs. The cut-off
point for the 6MWD was approximately 350 m [29] and
the minimal important difference in COPD patients is
25 m [30]. Currently, quality of life is an indispensable
indicator and assessment tool. Because of the long
course of COPD and a progressive decline in lung func-
tion, patients’ daily activities are limited and they rely on
on family members more, coupled with a financial bur-
den and decreased family status. COPD patients usually
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verse effects on psychological emotion and social adap-
tation ability. There are many types of effective and
reliable health related quality of life questionnaires on
chronic respiratory diseases [31]. With better reliability
and validity, the WHOQOL-BREF was adopted in the
current study to evaluate the quality of life of patients
with COPD. Our results showed that the improvement
of 6MWD in the trial group was 31.84 m, which, was
better than that 14.07 m in the control group. The im-
provement of quality of life was 13.26% in the trial group
and 6.13% in the control group, and symptoms were
reduced, with lower dyspnea scale scores in the trial
group compared with those in the control group. TCM
granules reduced symptoms, and improved exercise tol-
erance and health status.
In addition, the reasons for the favorable effects of
TCM treatment on the clinical parameters in COPD
patients were also taken into account. Our results sug-
gest that these favorable effects may be due to the com-
bined effect of conventional Western medicine and
Chinese medicines. The clinical effect of the TCM gran-
ules lied in reducing the frequency of acute exacerbation,
ameliorating symptoms, increasing exercise endurance,
and improving quality of life. In view of our previous
studies, the mechanism of the TCM granules may be
involved in reducing the expression of interleukin (IL)-8,
IL-6, IL-10, IL-1β and TNF-α, and regulating the level of
inflammatory cytokines. TCM granules may also be
involved in regulating the level of cellular immunity, es-
pecially the expression of T lymphocyte subsets (CD3+,
CD4+, CD8+, CD4+/CD8+) and CD4+CD25+; reducing
the expression of matrix metalloproteinase(MMP)-2,
MMP-9, improving the expression of tissue inhibitor of
metalloproteinases-1, regulating the balance of MMPs,
and reducing the expression of JAK/STAT signaling
pathways related factors and inflammatory factors.
Based on the the results of our trial, TCM treatment,
including Bu-Fei Jian-Pi granules, Bu-Fei Yi-Shen gran-
ules, and Yi-Qi Zi-Shen granules, is safe and effective for
treating COPD patients. However, there are some limita-
tions for this study. In this study, herbal interventions
(the granules) for the three TCM patterns were recog-
nized as whole comprehensive interventions rather than
one herbal intervention for each pattern. This study
aimed to evaluate comprehensive interventions based on
the three common patterns in stable COPD patients.
Therefore, the efficacy of each type of herbal interven-
tion on a TCM pattern was not evaluated. In addition,
the 6-month treatment duration and 12-month follow-
up duration was a little short to observe changes in lung
function and to show the fully effect of TCM treatment.
Further studies should be performed to evaluate TCM
treatment.Conclusions
Based on the TCM patterns, TCM treatments for COPD
are safe and effective. The curative effects of TCM were
mainly manifested by reducing the frequency and dur-
ation of acute exacerbation, ameliorating symptoms, and
improving exercise endurance, and quality of life. Fur-
ther studies are required to prove the efficacy and safety
of TCM treatments
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